

# Meijuan Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4019349/publications.pdf>

Version: 2024-02-01

63  
papers

1,208  
citations

567281

15  
h-index

434195

31  
g-index

71  
all docs

71  
docs citations

71  
times ranked

1800  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020, 26, 732-740.	30.7	322
2	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1296-1304.	7.0	79
3	Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 212-224.	0.8	72
4	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. <i>Translational Lung Cancer Research</i> , 2020, 9, 269-279.	2.8	64
5	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 321-328.	1.5	61
6	KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. <i>Nature Cancer</i> , 2022, 3, 753-767.	13.2	41
7	Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters. <i>Radiotherapy and Oncology</i> , 2019, 132, 197-203.	0.6	33
8	Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. <i>Lung Cancer</i> , 2016, 96, 93-100.	2.0	32
9	Targeted demethylation of the SARI promotor impairs colon tumour growth. <i>Cancer Letters</i> , 2019, 448, 132-143.	7.2	31
10	Mannan Loaded Biodegradable and Injectable Thermosensitive PCL-PEG-PCL Hydrogel for Vaccine Delivery. <i>Soft Materials</i> , 2012, 10, 472-486.	1.7	24
11	Rapid generation of functional hepatocyte-like cells from human adipose-derived stem cells. <i>Stem Cell Research and Therapy</i> , 2016, 7, 105.	5.5	22
12	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. <i>Oncotarget</i> , 2017, 8, 111309-111317.	1.8	22
13	Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 739090.	2.8	19
14	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. <i>Oncotarget</i> , 2017, 8, 49680-49688.	1.8	17
15	Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations. <i>Journal of Thoracic Oncology</i> , 2016, 11, e59-e62.	1.1	16
16	A Vesicular Stomatitis Virus-Inspired DNA Nanocomplex for Ovarian Cancer Therapy. <i>Advanced Science</i> , 2018, 5, 1700263.	11.2	16
17	<p></p>Targeted nanoparticle-mediated LHPP for melanoma treatment</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 3455-3468.	6.7	15
18	Rapid and high-efficiency generation of mature functional hepatocyte-like cells from adipose-derived stem cells by a three-step protocol. <i>Stem Cell Research and Therapy</i> , 2015, 6, 193.	5.5	14

#	ARTICLE	IF	CITATIONS
19	Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild-type EGFR and ALK. <i>Journal of Clinical Oncology</i> , 2019, 37, 9112-9112.	1.6	14
20	<i>In vitro</i> Release Behavior of Bovine Serum Albumin from Alginate/P(CE-MAA-MEG) Composite Hydrogel. <i>Soft Materials</i> , 2010, 8, 307-319.	1.7	12
21	Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes. <i>Thoracic Cancer</i> , 2016, 7, 515-521.	1.9	12
22	Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?. <i>Thoracic Cancer</i> , 2020, 11, 631-639.	1.9	11
23	Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with <i>B2M</i> and <i>STK11</i> mutations: a case report. <i>Immunotherapy</i> , 2020, 12, 223-227.	2.0	10
24	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 816-824.	1.4	9
25	Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method. <i>Translational Lung Cancer Research</i> , 2020, 9, 71-81.	2.8	9
26	Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations. <i>Frontiers in Oncology</i> , 2021, 11, 630256.	2.8	9
27	Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2589-2598.	2.5	9
28	Coexisting of <i>COX7A2L</i> – <i>ALK</i> , <i>LINC01210</i> – <i>ALK</i> , <i>ATP13A4</i> – <i>ALK</i> and Acquired <i>SLCO2A1</i> – <i>ALK</i> in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8313-8316.	2.0	8
29	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 36.	2.6	7
30	Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report. <i>Annals of Palliative Medicine</i> , 2020, 9, 3609-3613.	1.2	7
31	Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 93-102.	1.4	7
32	Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer. <i>Aging</i> , 2021, 13, 7397-7415.	3.1	7
33	Distribution and therapeutic outcomes of intergenic sequence- <i>ALK</i> fusion and coexisting <i>ALK</i> fusions in lung adenocarcinoma patients. <i>Lung Cancer</i> , 2021, 152, 104-108.	2.0	7
34	In Vitro Degradation Behavior of Polyesteramide Copolymer Fiber Based on 6-Aminocaproic Acid, Adipic Acid, and 1,6-Hexane Diol. <i>Journal of Polymer Research</i> , 2007, 14, 31-37.	2.4	6
35	Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen. <i>Thoracic Cancer</i> , 2013, 4, 234-240.	1.9	5
36	A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. <i>Investigational New Drugs</i> , 2020, 38, 478-484.	2.6	5

#	ARTICLE	IF	CITATIONS
37	The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review. <i>Annals of Palliative Medicine</i> , 2021, 10, 7088-7094.	1.2	5
38	Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib. <i>Frontiers in Oncology</i> , 2021, 11, 722843.	2.8	5
39	Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8015-8015.	1.6	5
40	Salvage treatment with erlotinib after gefitinib failure in advanced non-small cell lung cancer patients with poor performance status: A matched-pair case-control study. <i>Thoracic Cancer</i> , 2012, 3, 27-33.	1.9	4
41	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	1.8	4
42	Differential diagnosis of acute miliary pulmonary tuberculosis from widespread-metastatic cancer for postoperative lung cancer patients: two cases. <i>Journal of Thoracic Disease</i> , 2017, 9, E115-E120.	1.4	3
43	Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 421-426.	1.0	3
44	Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study,) <i>Tj ETQq0 0 0 rgBT /OverJock 10 Jf 50 462 T</i> 338-338.	1.7	3
45	A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2021, , 1.	2.6	3
46	Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20611-e20611.	1.6	3
47	Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 567-570.	1.0	2
48	Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?. <i>International Journal of Clinical Oncology</i> , 2018, 23, 258-265.	2.2	2
49	Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions. <i>Cancer Medicine</i> , 2020, 9, 8772-8781.	2.8	2
50	PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. <i>Scientific Reports</i> , 2020, 10, 16150.	3.3	2
51	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21154-e21154.	1.6	2
52	Marvelous objective response of low dose radiotherapy plus ICIs for extended stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21097-e21097.	1.6	2
53	Alveolar rhabdomyosarcoma of nasopharynx and paranasal sinuses with metastasis to breast in a middle-aged woman: a case report and literature review. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 15316-21.	0.5	2
54	Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI. <i>Frontiers in Oncology</i> , 2020, 10, 573512.	2.8	1

#	ARTICLE	IF	CITATIONS
55	Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, e20543-e20543.	1.6	1
56	Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study.. Journal of Clinical Oncology, 2021, 39, e21131-e21131.	1.6	0
57	Endostar plus gemcitabine/cisplatin (GP) with maintenance endostar as first-line therapy for advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study.. Journal of Clinical Oncology, 2012, 30, e18033-e18033.	1.6	0
58	How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation? A bicenter research and pooled analysis of published reports.. Journal of Clinical Oncology, 2017, 35, e20571-e20571.	1.6	0
59	Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study).. Journal of Clinical Oncology, 2022, 40, e21174-e21174.	1.6	0
60	Striking effect of low-dose radiotherapy combined with PD-1 blockade on small cell lung cancer in mice and refractory patients (Achilles Study).. Journal of Clinical Oncology, 2022, 40, e20608-e20608.	1.6	0
61	Abstract CT510: A phase I clinical trial of 3D-pluripotent stem cell biologics in heavily treated advanced NSCLC patients. Cancer Research, 2022, 82, CT510-CT510.	0.9	0
62	Abstract 5569: CAR-T cells with $\hat{I}\pm$ PDL1/CD28 switch-receptor synergize radiotherapy and anti-PD1 therapy in solid tumors. Cancer Research, 2022, 82, 5569-5569.	0.9	0
63	Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, single-arm, open-label study.. Journal of Clinical Oncology, 2022, 40, 9098-9098.	1.6	0